Mumbai, June 30, 2017: Pharma Major Glenmark Pharmaceuticals today said that the company has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets-5 mg and 10 mg, Solifenacin Succinate tablets are used for treatment of overactive bladder, company said in a filing with BSE. The company’s products are the generic version of Vesicare tablets, 5 mg and 10 mg of Astellas Pharma US Inc. According to IMS Health April 2017 sales data, the market for Vesicare tablets-5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. Glenmark’s current portfolio consists of 117 products authorised for distribution in the US marketplace, the company said, adding that it has 68 Abbreviated New Drug Applications (ANDA) pending with the USFDA
United News of India
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…